

Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

Information for the public

Published: 28 April 2021

www.nice.org.uk

Bempedoic acid with ezetimibe (Nilemdo and Nustendi) is available on the NHS as a possible treatment for primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended if:

- statins are contraindicated or not tolerated, and
- ezetimibe alone does not control low-density lipoprotein cholesterol well enough.

If you are not eligible for bempedoic acid with ezetimibe but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more

This organisation can give you advice and support: [Heart UK](#), 0345 450 5988

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4100-1